A Study of Safety, Functional and Anatomical Effect of Squalamine Lactate Ophthalmic Solution, 0.2% Administered Twice Daily in Subjects With Neovascular Age-related Macular Degeneration
Latest Information Update: 02 May 2017
Price :
$35 *
At a glance
- Drugs Squalamine (Primary) ; Ranibizumab
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Ohr Pharmaceutical
- 25 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment as per Company decision.
- 04 Aug 2015 New trial record